Clinical Trials Browser

Recruiting × Lung Neoplasms × olaparib × Clear all

NCT06217757 2026-05-05

Safety and Tolerability of LDRT+Sugemalimab+Chemotherapy+Olaparib for First-Line Treatment of SLFN-11 Positive ES-SCLC

Phase 1/2 Recruiting

Lung Neoplasms, Small Cell Lung Carcinoma

NCT04515836 2025-05-06

Olaparib in Patients With HRD Malignant Mesothelioma

Phase 2 Recruiting

Other solid neoplasmThoracic

Mesothelioma, Malignant, Lung Neoplasms, Mesothelioma